MAMichael Alfertshofer

Michael Alfertshofer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael Alfertshofer has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Christian Doll

    Department of Oral and Maxillofacial Surgery, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany

    2 shared publications
  • Max Heiland

    Department of Oral and Maxillofacial Surgery, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany

    2 shared publications
  • Adriana C. Panayi

    Department of Oral and Maxillofacial Surgery, Charité—Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany

    1 shared publication
  • Alexander G. M. Hopf

    Institute of Psychology, University of Innsbruck, Innsbruck, Austria

    1 shared publication
  • Alexandre Gaston Lellouch

    Division of Plastic and Reconstructive Surgery, Cedars-Sinai Medical Center, Los Angeles, USA

    1 shared publication
  • Benedikt Geldner

    Department of Oral and Maxillofacial Surgery, Charité—Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany

    1 shared publication

Latest Publications

  • Open Access

    Beyond reconstruction: minimally invasive aesthetic and regenerative medicine in postoperative oral and maxillofacial surgery

    by Michael Alfertshofer, Alexander G. M. Hopf, Kilian Kreutzer, Carolin Bestendonk, Christian Doll, Sebastian Cotofana, Norbert Neckel, Max Heiland, Marietta Hopf

    Purpose: Oral and maxillofacial reconstruction restores anatomical continuity and function after tumor resection, trauma and congenital deformity, yet patients frequently remain affected by fibrosis, scar tethering, impaired oral competence, asymmetry and altered dynamic facial function. These deficits can impair quality of life, social interaction and body image. Conventional revision surgery carries additional morbidity, and minimally invasive options have emerged as a postoperative adjunct. This article reviews how minimally invasive aesthetic and regenerative medicine can extend reconstructive rehabilitation in oral and maxillofacial surgery. Methods: Current biological and clinical evidence for polynucleotides (PN), hyaluronic acid (HA) and botulinum toxin A (BoNT-A) was reviewed and integrated with selected, non-consecutive illustrative cases from a dedicated aesthetic and regenerative consultation in an academic oral and maxillofacial surgery department. Clinical applications were illustrated across four patient categories: oncological, congenital, trauma/scar and aesthetic-functional sequelae after surgery. Results: In illustrative cases from different categories, a staged approach of tissue conditioning, structural restoration and dynamic neuromodulation was associated with clinically observed and patient-reported improvements in scar pliability, tissue gliding, oral competence, dynamic symmetry and quality of life. PN were used primarily for regenerative tissue conditioning, HA for reversible structural restoration, and BoNT-A to modulate muscular imbalance and pathological wound tension. As interventions were frequently combined and no validated outcome measures or controls were used, these observations are hypothesis-generating. Conclusion: Minimally invasive regenerative and aesthetic treatment may serve as a functional extension of reconstruction rather than a cosmetic adjunct. The central concept is not volumisation, but restoration of tissue quality, dynamic balance and facial function. Prospective studies using validated functional, scar and patient-reported outcome measures are required to define its role in modern oral and maxillofacial surgery.

  • Open Access

    Programmed Death-Ligand 1 (PD-L1) expression and clinical outcomes in oral squamous cell carcinoma: evidence from a large clinical cohort

    by Michael Alfertshofer, Maximilian Richter, Konrad Klinghammer, Christian Doll, Steffen Koerdt, Max Heiland, Friedrich Mrosk

    Background: Despite the recognized biological relevance of the PD-1/PD-L1 axis in immune evasion, the prognostic significance of PD-L1 expression in surgically treated oral squamous cell cancer (OSCC) patients remains largely unclear. Objective: To investigate the prognostic significance of PD-L1 expression in a large cohort of OSCC patients primarily treated surgically in a single center. Methods: This analysis included 156 consecutive OSCC patients treated with curative-intent surgery with their clinicopathologic variables, treatment details and clinical treatment outcomes. PD-L1 expression was categorized using the Combined Positive Score (CPS), defining PD-L1 positivity as CPS ≥ 10. Sensitivity analyses were repeated at the alternative thresholds CPS ≥ 1 and CPS ≥ 20. Survival and recurrence endpoints (OS, DFS, LRCR, NCR) were evaluated using Kaplan–Meier/log-rank methods and Cox regression with multivariable adjustment for key confounders. Results: Of 156 consecutive OSCC patients, 120 (76.9%) were PD-L1-positive. PD-L1 status was not associated with any clinicopathological parameter investigated herein. At 3 years, OS (76.1% vs. 68.7%), DFS (63.5% vs. 42.6%), LRCR (77.1% vs. 75.5%), and NCR (93.0% vs. 91.0%) were comparable between PD-L1-positive and PD-L1-negative patients, respectively. Neither binary PD-L1 classification nor continuous CPS was associated with OS, DFS, LRCR, or NCR in multivariable Cox regression, with no differential effect by disease stage. In adjuvant-treatment-stratified analysis, PD-L1 positivity was associated with improved DFS in patients without adjuvant therapy, but not in those who received it. In sensitivity analyses, findings at CPS ≥ 20 were concordant with the primary analysis, whereas at CPS ≥ 1 PD-L1 positivity was associated with superior OS (HR = 0.280 [95% CI: 0.106–0.745]; p = 0.011). Conclusion: Within a mean follow-up of 15.7 ± 12.5 months, PD-L1 expression assessed by CPS was not independently associated with survival or recurrence outcomes in surgically treated OSCC at the prespecified cutoff of CPS ≥ 10, nor at CPS ≥ 20. An isolated overall survival association at CPS ≥ 1 was driven by a very small PD-L1-negative reference group and should not be regarded as robust. Taken together, these data argue against a reliable standalone prognostic value of PD-L1 in the early postoperative period while the limited observation time does not permit conclusions on late recurrence or long-term survival.

  • Bone Grafting in Le Fort I Osteotomies: Multi-Institutional Data Analysis of Early Outcomes and Risk Factors

    by Simon Bigus, Leonard Knoedler, Michael Alfertshofer, Helena Baecher, Tanas Ghassemi, Claudius Steffen, Samuel Knoedler, Benedikt Geldner, Alexandre G. Lellouch, Max Heiland, et al.

    Background: The Le Fort I osteotomy is a standard approach for treating the maxilla in orthognathic surgery. Achieving stable ossification, particularly in cases requiring significant movements, can be clinically challenging and may compromise the ossification process. Despite the clinical significance of this issue, there remains a lack of robust multicenter studies directly comparing outcomes of Le Fort I osteotomies performed with versus without bone grafting (BG). Methods: In this study, the authors accessed the ACS-NSQIP database from 2008 to 2023 to identify patients who underwent isolated surgical Le Fort I osteotomy with and without BG. Collected data included demographics, comorbidities, surgical characteristics, and 30-day postoperative outcomes. Results: Of 418 patients who underwent an isolated Le Fort I osteotomy, 95 patients (22.7%) underwent augmentation of the gap using BG, while 323 patients (77.3%) underwent surgery without BG. Overall, 13 (4.0%) non-BG and 7 (7.4%) BG patients experienced any complication ( P =0.88). In a multivariable analysis of all study cases, longer hospital stays ( P P =0.02) and obesity ( P =0.04) were found to be independent risk factors for the occurrence of surgical complications. Conclusion: The Le Fort I osteotomy is an overall safe procedure. In this study, the use of BG did not appear to increase the risk of postoperative complications compared with procedures performed without BG. Identified risk factors for postoperative complications are prolonged hospital stays, higher BMI, and obesity.

  • Open Access

    Horizontal vascular-stalked split osteotomy (HVSO): a bone augmentation technique for the atrophic jaw– a retrospective cohort study in 29 patients

    by Dirk Nolte, Johannes Angermair, Heidi Bradatsch, Rolf Ewers, Michael Alfertshofer, Robert Linsenmann, Sven Otto, Karin Christine Huth

    Background: Implant therapy in the advanced atrophic jaw remains challenging in oral and maxillofacial surgery. Hence, a plethora of different augmentation procedures to increase bone volume in the maxilla and mandible have been published. Horizontal vascular-stalked split osteotomy (HVSO) represents a safe and effective approach for the three-dimensional jaw augmentation since it combines maximum vascularization through lingual or palatinal periosteal stalking with reduced grafting morbidity. Objective: To analyze the efficacy of HVSO for implantation therapy in atrophic jaws by assessing vertical bone gain and implant survival rates. Materials and methods: A total of n = 29 patients (14 females, 15 males) with a mean age of 55.4 ± 10.0 years and reduced volume of the alveolar ridge were retrospectively analyzed after treatment with 34 HVSOs in the maxilla and mandible. After controlled clinical follow-up of six months after augmentation, enossal implantation of 79 implants (maxilla 45, mandible 34) was performed. A standardized two-dimensional radiological assessment with panoramic tomography (OPTG) of the augmented bone height and clinical evaluation of the implants was performed over a mean follow-up period of 2.3 years. Results: HVSO resulted in a significant increase in vertical bone height by 4.4 mm ± 2.0 mm (mean vertical gain: +59.4%) with + 101% in the maxilla and + 27.5% in the mandible directly after the procedure (T1), with both p < 0.001. After a mean observation period of 2.3 years bone height remained stable with a total gain of 41.4% (maxilla: 72.6%, mandible: 18.6%), with p < 0.001 and p = 0.001, respectively. Overall implant survival rate was 91% (maxilla: 89%; mandible: 94%). Conclusion: HVSO reliably supports significantly enhanced vertical bone height with long-term stable results, thereby facilitating successful implantation in atrophic jaws with high implant survival rates observed over an extended follow-up period. Clinical Trial Number: Not applicable as the study was no clinical trial.